DNA-based carrier screening in primary healthcare: Screening for aspartylglucosaminuria mutations in maternity health offices

Clinical Chemistry

Volumn 42, Issue 9, 1996, Pages 1398-1404

  Hietala, Marja ^a   Aula, Pertti ^a   Syvänen, Ann Christine ^b   Isoniemi, Annukka ^b   Peltonen, Leena ^b   Palotie, Aarno ^c,d  

^a UNIVERSITY OF TURKU   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

genetic testing; hereditary disorders; mutation detection; polymerase chain reaction

Indexed keywords

ARTICLE; ASPARTYLGLYCOSAMINURIA; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE MUTATION; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MATERNITY WARD; POLYMERASE CHAIN REACTION; PRIMARY HEALTH CARE;

EID: 0029757142     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.9.1398     Document Type: Article

References (38)

1. Williamson R. Universal community carrier screening for cystic fibrosis? [Review]. Nature Genet 1993;3:195-201.
2. Syvänen A-C, Aalto-Setälä K, Harju L, Kontula K, Söderlund H. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics 1990;8:684-92.
3. 1-antitrypsin Z mutation. Clin Chem 1993;39:2282-7.
4. Syvänen A-C, Ikonen E, Manninen T, Bengtström M, Söderlund H, Aula P, Peltonen L. Convenient and quantitative determination of the frequency of a mutant allele using solid-phase minisequencing: application to aspartylglucosaminuria in Finland. Genomics 1992;12:590-5.
5. 654 → A) mutation of gelsolin in all affected individuals with Finnish type of familial amyloidosis. Genomics 1992;13:237-9.
6. Vesa J, Hellsten E, Verkruyse LA, Camp LA, Rapola J, Santavuori P, et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 1995; 376:584-7.
7. Tatlisumak T, Syrjälä M, Lindsberg P, Palotie A, Kaste M. FV-ARG-506-GLN mutation-associated resistance to activated protein C in ischemic stroke. J Stroke Cerebrovasc Dis 1995;5:192-6.
8. Lys point mutation in myoclonus epilepsy and ragged-red-fiber disease. Eur J Hum Genet 1993;1:88-95.
9. Juvonen V, Huoponen K, Syvänen A-C, Nikoskelainen E, Savontaus M-L. Quantification of point mutations associated with Leber hereditary optic neuroretinopathy by solid-phase minisequencing. Hum Genet 1994;93:16-20.
10. Jalanko A, Kere J, Savilahti E, Schwartz M, Syvänen A-C, Ranki M, Söderlund H. Screening for defined cystic fibrosis mutations by solid-phase minisequencing. Clin Chem 1992;38:39-43.
11. Ihalainen J, Taavitsainen M, Salmivaara T, Palotie A. Diagnosis of pancreatic lesions using fine needle aspiration cytology: detection of K-ras point mutations using solid phase minisequencing. J Clin Pathol 1994;47:1082-4.
12. Syvänen A-C, Sajantila A, Lukka M. Identification of individuals by analysis of biallelic DNA markers, using PCR and solid-phase minisequencing. Am J Hum Genet 1993;52:46-59.
13. Ihalainen J, Siitari H, Laine S, Syvänen A-C, Palotie A. Towards automatic detection of point mutations: use of scintillating microplates in solid-phase minisequencing. BioTechniques 1994;16: 938-43.
14. Norio R, Nevanlinna HR, Perheentupa J. Hereditary diseases in Finland; rare flora in rare soil. Ann Clin Res 1973;5:109-41.
15. Mitchell G, Brody L, Sipilä I, Looney JE, Wong C, Engelhardt JF, et al. At least two mutant alleles of ornithine D-aminotransferase cause gyrate atrophy of the choroid and retina in Finns. Proc Natl Acad Sci U S A 1989;86:197-201.
16. Maury CPJ, Kere J, Tolvanen R, de la Chapelle A. Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene. FEBS Lett 1990;276:75-7.
17. Kure S, Takayanagi M, Narisawa K, Tada K, Leisti J. Identification of a common mutation in Finnish patients with nonketotic hyperglycinemia. J Clin Invest 1992;90:160-4.
18. Pollitt RJ, Jenner FA. Aspartylglycosaminuria. An inborn error of metabolism associated with mental defect. Lancet 1968;ii: 253-5.
19. Aula P, Autio S, Raivio KO, Rapola J. Aspartylglucosaminuria. In: Durand P, O'Brien JS, eds. Genetic errors of glycoprotein metabolism. Berlin: Springer, 1982:122-52.
20. Hietala M, Grön K, Syvänen A-C, Peltonen L, Aula P. Prospects of carrier screening of aspartylglucosaminuria in Finland. Eur J Hum Genet 1993;1:296-300.
21. Ikonen E, Baumann M, Grön K, Syvänen A-C, Enomaa N, Halila R, et al. Aspartylglucosaminuria: cDNA encoding human aspartylglucosaminidase and the missense mutation causing the disease. EMBO J 1991;10:51-8.
22. Isoniemi A, Hietala M, Aula P, Jalanko A, Peltonen L. Identification of a novel mutation causing aspartylglucosaminuria reveals a mutation hotspot region in the aspartylglucosaminidase gene. Hum Mutat 1995;5:318-26.
23. Kaback M, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zeiger K. Tay-Sachs disease - carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. JAMA 1993;270:2307-15.
24. Cao A, Rosatelli MC. Screening and prenatal diagnosis of the haemoglobinopathies. Baillieres Clin Haematol 1993;6:263-86.
25. Mahuran DJ, Triggs-Raine BL, Feigenbaum A, Gravel RA. The molecular basis of Tay-Sachs disease: mutation identification and diagnosis. Clin Biochem 1990;23:409-15.
26. Chehab FF, Wall J. Detection of multiple cystic fibrosis mutations by reverse dot blot hybridization: a technology for carrier screening. Hum Genet 1992;89:163-8.
27. Ferrie RM, Schwarz MJ, Robertson NH, Vaudin S, Super M, Malone G, Little S. Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene. Am J Hum Genet 1992;51:251-62.
28. Axton RA, Brock DJH. A single-tube multiplex system for the simultaneous detection of 10 common cystic fibrosis mutations. Hum Mutat 1995;5:260-2.
29. Mennie ME, Gilfillan A, Compton M, Curtis L, Liston WA, Pullen I, et al. Prenatal screening for cystic fibrosis. Lancet 1992;340: 214-6.
30. Livingstone J, Axton RA, Gilfillan A, Mennie M, Compton M, Liston WA, et al. Antenatal screening for cystic fibrosis: a trial of the couple model. Br Med J 1994;308:1459-62.
31. Super M, Schwarz MJ, Malone G, Roberts T, Haworth A, Dermody G. Active cascade testing for carriers of cystic fibrosis gene. Br Med J 1994;308:1462-8.
32. Miedzybrodzka ZH, Hall MH, Mollison J, Templeton A, Russell IT, Dean JCS, et al. Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. Br Med J 1995;310:353-7.
33. Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence specific oligonucleotide probes. Proc Natl Acad Sci U S A 1989;86:6230-4.
34. Chehab FF, Doherty M, Cai S, Kan YW, Cooper S, Rubin EM. Detection of sickle cell anaemia and thalassaemias. Nature 1987;329:293-4.
35. Haliassos A, Chomel JC, Tesson L, Baudis M, Kruh J, Kaplan JC, Kitzis A. Modification of enzymatically amplified DNA for the detection of point mutations. Nucleic Acids Res 1989;17:3606.
36. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res 1989;17:2503-16.
37. Southern EM. DNA chips: analysing sequence by hybridization to oligonucleotides on a large scale. Trends Genet 1996;12:110-5.
38. Hietala M, Hakonen A, Aro AR, Niemelä P, Peltonen L, Aula P. Attitudes toward genetic testing among the general population and relatives of patients with a severe genetic disease: a survey from Finland. Am J Hum Genet 1995;56:1493-500.